Nelson M Oyesiku Selected Research

Nelson M Oyesiku Research Topics

Disease

18	Neoplasms (Cancer) 09/2021 - 07/2003
17	Pituitary Neoplasms (Pituitary Adenoma) 04/2022 - 01/2003
7	Adenoma (Adenomas) 01/2022 - 07/2003
5	Acromegaly 01/2022 - 12/2012
3	Pituitary ACTH Hypersecretion 04/2022 - 09/2021
2	ACTH-Secreting Pituitary Adenoma 09/2021 - 08/2012
2	Headache (Headaches) 06/2019 - 10/2016
2	Residual Neoplasm 10/2016 - 08/2012
2	Prolactinoma (Prolactinomas) 08/2012 - 01/2008
1	Arthrogryposis renal dysfunction cholestasis syndrome 01/2022
1	Cushing Syndrome 06/2019
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 06/2019
1	Ganglion Cysts (Ganglion) 10/2018
1	Necrosis 01/2018
1	Infections 01/2017
1	Pneumocephalus 01/2017
1	Venous Thrombosis (Deep-Vein Thrombosis) 01/2017
1	Hyperprolactinemia 10/2016
1	Hypopituitarism (Sheehan's Syndrome) 10/2016
1	Meningioma (Meningiomas) 04/2014
1	Rhinosinusitis 05/2013
1	Hypercalcemia (Milk Alkali Syndrome) 12/2012
1	Growth hormone excess 12/2012
1	Hypothyroidism 01/2012
1	Intracranial Arteriovenous Malformations (Cerebral Arteriovenous Malformation) 01/2005
1	Brain Edema (Cerebral Edema) 10/2004
1	Traumatic Brain Injuries (Traumatic Brain Injury) 10/2004
1	Brain Contusion 10/2004

Drug/Important Bio-Agent (IBA)

7	Adrenocorticotropic Hormone (ACTH)FDA Link 04/2022 - 08/2012
6	Proteins (Proteins, Gene)FDA Link 11/2009 - 01/2003
4	Folic Acid (Vitamin M)FDA LinkGeneric 11/2010 - 07/2003
4	Messenger RNA (mRNA)IBA 11/2009 - 01/2003
3	Growth Hormone (Somatotropin)IBA 01/2022 - 07/2003
3	ProlactinIBA 06/2019 - 07/2003
3	CalciumIBA 01/2017 - 12/2012
3	Dopamine Agonists (Dopamine Agonist)IBA 10/2016 - 08/2012
2	theasinensin AIBA 09/2015 - 12/2012
2	Pituitary HormonesIBA 05/2013 - 07/2003
2	Transcription Factors (Transcription Factor)IBA 04/2013 - 08/2012
2	OligonucleotidesIBA 01/2008 - 11/2005
1	Hydrocortisone (Cortisol)FDA LinkGeneric 04/2022
1	styrene-co-maleic acid-co-methacrylate polymerIBA 09/2021
1	Insulin-Like Growth Factor I (IGF-1)IBA 01/2020
1	Prednisone (Sone)FDA LinkGeneric 06/2019
1	Glucose (Dextrose)FDA LinkGeneric 06/2019
1	Retinaldehyde (Retinal)IBA 10/2018
1	Angiotensin Receptors (Angiotensin II Receptor)IBA 01/2018
1	Phosphorus (Red Phosphorus)IBA 01/2017
1	calcium phosphateIBA 01/2017
1	Biomarkers (Surrogate Marker)IBA 10/2016
1	Insulin-Like PeptidesIBA 10/2016
1	Chromogranin AIBA 10/2016
1	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 10/2016
1	Glycoproteins (Glycoprotein)IBA 04/2016
1	Anti-Bacterial Agents (Antibiotics)IBA 05/2013
1	Pro-Opiomelanocortin (Proopiomelanocortin)IBA 04/2013
1	Melanocyte-Stimulating Hormones (MSH)IBA 04/2013
1	hydroxide ionIBA 12/2012
1	1,25-dihydroxyvitamin DIBA 12/2012
1	Dopamine (Intropin)FDA LinkGeneric 08/2012
1	Estrogens (Estrogen)FDA Link 08/2012
1	Thyrotropin (Thyroid-Stimulating Hormone)FDA Link 01/2012
1	Folate Receptor 1IBA 11/2009
1	Protein Isoforms (Isoforms)IBA 06/2008
1	Transcription Factor Pit-1 (Transcription Factor Pit 1)IBA 01/2008
1	Biological ProductsIBA 01/2008
1	Cadherins (E-Cadherin)IBA 01/2008
1	AgarIBA 01/2008
1	Progesterone FDA LinkGeneric 10/2004
1	Pregnanolone (Allopregnanolone)IBA 10/2004
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2004
1	CytokinesIBA 10/2004
1	salicylhydroxamic acid (SHAM)IBA 10/2004
1	Interleukin-1beta (Interleukin 1 beta)IBA 10/2004
1	Anterior Pituitary HormonesIBA 07/2003
1	VitaminsIBA 07/2003
1	Hormones (Hormone)IBA 07/2003
1	Complementary DNA (cDNA)IBA 07/2003
1	SecretagoginsIBA 01/2003

Therapy/Procedure

6	Radiotherapy 01/2022 - 10/2012
4	Therapeutics 01/2017 - 01/2008
2	Particle Accelerators 01/2022 - 01/2005
1	Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated) 01/2022
1	Adjuvant Radiotherapy 01/2022
1	Endoscopes 10/2019
1	Length of Stay 01/2017
1	Aftercare (After-Treatment) 01/2017
1	Drug Tapering 08/2016
1	Drug Therapy (Chemotherapy) 05/2013